RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing & Expansion Facility in Japan to Advance RCH-01, a...
20 Maio 2014 - 9:00AM
Marketwired
RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell
Processing and Expansion Facility in Japan to Advance RCH-01, a
Treatment for Pattern Baldness
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 20, 2014) -
RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSX-VENTURE:RP) a
clinical stage regenerative medicine company focused on the
development of autologous cell therapies, is pleased to announce
that its RCH-01 licensing partner, Shiseido, celebrated the opening
of its new cell-processing facility at the Kobe Biomedical
Innovation Cluster (KBIC) located on Port Island, Japan on May 18,
2014. Dignitaries, physicians, partner companies, and government
representatives were in attendance at this important event.
Shiseido's state-of-the-art facility will focus on the continued
research and development, and the commercialization of RepliCel's
RCH-01 hair regeneration technology.
"Shiseido has been working diligently on the construction of
their facility and we congratulate them on their efficiency and
commitment to building a world-class cell research and development
centre capable of handling all aspects of the RCH-01 technology
from hair follicle biopsy through to cell replication and patient
treatment," commented David M. Hall, CEO of RepliCel Life Sciences.
"We continue to support Shiseido with its highly focused
development towards commercialization of RCH-01 as a treatment for
pattern baldness."
The KBIC is a complex of medical-related industries located on
the 833-hectare man-made island of Port Island in Kobe, Japan.
Working in cooperation with academic research institutions,
government organisations, and industry, the island has been
developed as a focal point for research and development of highly
advanced medical technologies with the goal of streamlining
processes from research to clinical application and
commercialization.
Regenerative medicine in Japan is an emerging industry which the
government has designated as an important part of its economic
reform. Legislative support has come from the introduction of new
laws to expedite otherwise lengthy clinical research and trial
application processes to promote competitive advantage in the
international market. In November 2013, as one of the new economic
reform strategies, the Japanese government passed the Regenerative
Medicine Law, which ensures safety of regenerative medicine, and
approved revisions to its existing Pharmaceutical Affairs Law to
improve the timelines for the development of regenerative medicine
and to promote commercialization. Shiseido has entered into this
field via its licensing agreement with RepliCel and is committed to
its advancement and success.
Licensing Agreement
On July 11, 2013, RepliCel and Shiseido announced the completion
of a Collaboration and Technology Transfer Agreement, giving
Shiseido an exclusive geographic license to use RCH-01 hair
regeneration technology in Japan, China, South Korea, Taiwan and
the ASEAN countries Shiseido and RepliCel will collaborate on the
continued improvement of the technology and will conduct human
clinical trials in each of their territories with the goal of
commercializing a safe and effective hair regenerative treatment to
help those suffering from pattern baldness and thinning hair.
RCH-01 has been developed over 10 years of scientific research,
and safe application in humans was validated during RepliCel's
phase 1 clinical trial. RepliCel has patents issued for hair
follicle mesenchymal stem cells and their usage in Japan, the
United States, Australia and the EU. RCH-01 is an autologous
cell-based hair regenerative technology whereby specific hair
follicle cells are isolated from a scalp biopsy, expanded in
culture at a cell processing facility and injected back into
patients.
About the Kobe Biomedical Innovation Cluster and Shiseido's
Facility
More than 260 domestic and international companies have built
R&D facilities focusing on regenerative medicine,
pharmaceuticals, medical equipment and devices in the research
park, taking advantage of the opportunities for collaboration and
synergy that the KBIC fosters. Centralised support services
facilitate clinical research, commercialisation, consultations on
pharmaceutical development issues and financing, and the
establishment of comprehensive platforms for biomedical research
and development. The Business Support Centre for Biomedical
Research Activities has been built to support and to provide space
for research and commercialization of regenerative medicine. This
facility is divided into two sections, research and
cell-processing. Shiseido's Cell-Processing and Expansion Centre
(SPEC) is located in the cell processing section, Room 620, 1-5-5
Minamimachi, Minatojima, Chuoku, Kobe, 650-0047, Japan.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on
developing autologous cell therapies that treat functional cellular
deficits including chronic tendinosis, pattern baldness and skin
aging. Initiation of Phase 2 trials are planned for 2014 on
RepliCel's RCT-01 treatment for Achilles tendinosis and RCH-01
treatment for pattern baldness. Shiseido Company, Limited has an
exclusive geographic license for RCH-01 in certain Asian countries
including Japan, China and South Korea. Both product candidates are
based on RepliCel's innovative technology which utilizes cells
isolated from a patient's own healthy hair follicles to address
specific cellular deficits. These products are built on the
company's proprietary manufacturing platforms. For additional
information please visit www.replicel.com.
Neither the TSX Venture Exchange Inc. nor its Regulation
Service Provider (as that term is defined in the policies of the
TSX Venture Exchange Inc.) accepts responsibility for the adequacy
or accuracy of this press release.
This press release contains forward-looking information that
involve various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of RepliCel, such as the statement that RepliCel is
seeking additional financing. There are numerous risks and
uncertainties that could cause actual results and RepliCel's plans
and objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) the inability of RepliCel to complete the private
placement at all or on the terms announced; or (iii) the TSX
Venture Exchange not approving further private placements. Actual
results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, RepliCel does not intend to update these forward-looking
statements.
COMPANY CONTACTS:David M. Hall, Chief Executive OfficerTammey
George, Director of CommunicationsRepliCel Life
Sciences604-248-8696tg@replicel.comINVESTOR CONTACT:Westwicke
Partners, LLCRobert H. UhlManaging
Director858-356-5932robert.uhl@westwicke.com
RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024